Renalytix - Return on Tangible Equity 2020-2024 | RNLXY
Current and historical return on tangible equity values for Renalytix - (RNLXY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Renalytix - Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $-0.03B | $-0.01B | 294.74% |
| 2024-06-30 | $-0.03B | $-0.01B | 471.43% |
| 2024-03-31 | $-0.04B | $-0.01B | 1138.46% |
| 2023-12-31 | $-0.04B | $-0.01B | -1025.00% |
| 2023-09-30 | $-0.04B | $0.00B | -521.21% |
| 2023-06-30 | $-0.05B | $0.01B | -339.62% |
| 2023-03-31 | $-0.04B | $0.02B | -202.60% |
| 2022-12-31 | $-0.04B | $0.01B | -190.91% |
| 2022-09-30 | $-0.05B | $0.02B | -150.40% |
| 2022-06-30 | $-0.05B | $0.03B | -108.43% |
| 2022-03-31 | $-0.05B | $0.03B | -97.09% |
| 2021-12-31 | $-0.04B | $0.05B | -68.48% |
| 2021-09-30 | $-0.04B | $0.06B | -51.01% |
| 2021-06-30 | $-0.04B | $0.07B | -43.08% |
| 2021-03-31 | $-0.03B | $0.08B | -41.48% |
| 2020-12-31 | $-0.02B | $0.09B | -42.11% |
| 2020-09-30 | $-0.02B | $0.09B | -62.14% |
| 2020-06-30 | $-0.01B | $0.02B | -250.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.044B | $0.003B |
| Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Renalytix plc, formerly known as RENALYTIX AI, is based in NEW YORK. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.674B | 59.39 |
| Tempus AI (TEM) | United States | $12.352B | 0.00 |
| Doximity (DOCS) | United States | $9.545B | 39.50 |
| Hims & Hers Health (HIMS) | United States | $8.883B | 72.26 |
| IRhythm Technologies (IRTC) | United States | $5.771B | 0.00 |
| Hinge Health (HNGE) | United States | $3.320B | 0.00 |
| Heartflow (HTFL) | United States | $2.981B | 0.00 |
| Privia Health (PRVA) | United States | $2.979B | 186.31 |
| Inspire Medical Systems (INSP) | United States | $2.642B | 43.71 |
| 10x Genomics (TXG) | United States | $2.078B | 0.00 |
| Enovis (ENOV) | United States | $1.787B | 9.38 |
| Omnicell (OMCL) | United States | $1.654B | 33.82 |
| Azenta (AZTA) | United States | $1.410B | 61.54 |
| Phreesia (PHR) | United States | $1.387B | 0.00 |
| Schrodinger (SDGR) | United States | $1.323B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.286B | 0.00 |
| Claritev (CTEV) | United States | $0.966B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.899B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.571B | 0.00 |
| Talkspace (TALK) | United States | $0.562B | 113.00 |
| Veradigm (MDRX) | United States | $0.536B | 0.00 |
| Evolent Health (EVH) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.454B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.369B | 0.00 |
| Carlsmed (CARL) | United States | $0.328B | 0.00 |
| TruBridge (TBRG) | United States | $0.303B | 13.93 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.292B | 0.00 |
| CapsoVision (CV) | United States | $0.259B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.243B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.201B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.195B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.175B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.174B | 0.00 |
| CareCloud (CCLD) | United States | $0.136B | 7.45 |
| EUDA Health Holdings (EUDA) | Singapore | $0.110B | 0.00 |
| Outset Medical (OM) | United States | $0.101B | 0.00 |
| Pulmonx (LUNG) | United States | $0.080B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.076B | 0.00 |
| American Well (AMWL) | United States | $0.066B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.055B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.038B | 0.00 |
| 111 (YI) | China | $0.035B | 0.00 |
| Precipio (PRPO) | United States | $0.032B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.028B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.021B | 0.00 |
| Zhongchao (ZCMD) | China | $0.017B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.015B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Movano (MOVE) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |